Elios Vision announces ELIOS registration in France


The technology is used to treat glaucoma at the same time as cataract surgery.

Elios Vision announces the registration of its ELIOS technology in France.

The technology, which is used to treat glaucoma at the same time as cataract surgery, does not require an implant and provides long-lasting results that may free patients and their doctors from the demands of drop therapy.1 ELIOS technology uses excimer laser energy to create microscopic openings in the trabecular meshwork to re-establish the natural flow of aqueous.

“The ELIOS procedure is filling the gap for patients who don’t need an aggressive surgical approach but are not doing well with drop therapy or would be much better off reducing their drop regimen,” said Ike Ahmed, MD, a Canada-based ophthalmologist and glaucoma expert. “ELIOS has been particularly impactful for cataract surgery in my practice. It just makes sense to combine ELIOS with cataract surgery when you’re already going into the eye.”

ELIOS provides an opportunity to address the most common cause of blindness during the most performed surgical procedure in the world with a safety profile similar to cataract surgery.2

“Multiple clinical studies across Europe have demonstrated that ELIOS has a strong efficacy and safety profile, with significant advantages over other forms of microinvasive glaucoma surgery,” said Elliot Friedman, chief executive officer of Elios Vision.

The technology is implant-free, meaning a faster learning curve for surgeons and less potential post-operative management for patients. In addition, ELIOS’ use of an excimer laser avoids thermal or mechanical trauma.1 The ten microchannels this technology creates have proven to be effective and long-lasting for up to 8 years.2

“The ELIOS technology appears to be a promising technology for lowering IOP and medication use in patients with glaucoma and has been used in other EU countries for several years. The fact that ELIOS uses a laser to enhance outflow is appealing as this makes the procedure less traumatic than conventional methods and avoids the use of implants,” said Prof Philippe Denis, glaucoma specialist, Hôpital de la Croix-Rousse, Lyon, France.

  1. Töteberg-Harms et al. BMC Ophthalmology 2013
  2. Riesen M, Funk J, Töteberg-Harms M. “Long-term treatment success and safety of combined phacoemulsification plus excimer laser trabeculostomy: an 8-year follow-up study”. Graefes Arch Clin Exp Ophthalmol. 2022 Jan 16.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.